Intro to Ophthalmic NDDS - Eye Spy New Ways
- Ophthalmic NDDS: Advanced formulations/devices designed to optimize ocular drug delivery, overcoming limitations of traditional eye drops (e.g., rapid precorneal clearance).
- Importance: Essential for effective management of anterior/posterior segment diseases, improving therapeutic outcomes.
- Key Advantages:
- ↑ Bioavailability, sustained drug levels.
- ↓ Dosing frequency → ↑ patient adherence.
- Targeted delivery, minimizing off-target effects.
- Reduced systemic toxicity & local irritation.
- Core Challenges:
- Formidable ocular barriers (tear film, cornea, blood-ocular barriers).
- Drug stability, sterility, biocompatibility.
- Patient acceptance & cost-effectiveness.
⭐ Primary advantage: Enhanced bioavailability and reduced dosing frequency, leading to improved patient compliance and therapeutic efficacy.
Anterior Segment NDDS - Front Door Delivery
| Feature | Contact Lenses (CLs) | Ocular Inserts (e.g., Ocusert) | Punctal Plugs | In-situ Gels |
|---|---|---|---|---|
| Form | Drug-eluting; soft/rigid | Solid, polymeric; erodible/non | Biocompatible; occludes puncta | Liquid → gel (pH, temp, ion trigger) |
| Mechanism | ↑ Contact time, sustained release | Cul-de-sac placement; prolonged use | Blocks tear drainage; ↑ drug retention | ↑ Viscosity, ↑ precorneal residence time |
| Pros | ↑ Bioavailability, convenience | Zero-order release, ↓ dosing freq. | Minimally invasive, targeted | Easy application, ↑ contact time |
| Cons | Lens issues, limited drug capacity | Foreign body sensation, expulsion | Expulsion, irritation | Initial blur, variable gelation |
| Examples | Glaucoma, dry eye, antibiotic CLs | Pilocarpine (Ocusert), Lacrisert | Dexamethasone insert, glaucoma plugs | Timolol, Moxifloxacin gels |
Posterior Segment NDDS - Backstage Pass Drugs
- Key approaches to overcome barriers for drug delivery to retina/choroid.
| System | Delivery & Duration | Pros | Cons | Examples |
|---|---|---|---|---|
| Intravitreal Inj. | Direct bolus; Weeks-Months | Rapid onset, High local conc. | Repeated, Endophthalmitis risk, IOP ↑ | Anti-VEGFs (Ranibizumab, Aflibercept) |
| Implants (Bio) | Sustained release, degrades; Months | No removal needed, Predictable release | Initial burst, Inflammation | Ozurdex (Dexamethasone 0.7 mg) |
| Implants (Non-Bio) | Sustained release, needs removal; Months-Years | Longest duration, Stable release | Surgical removal, Fibrosis risk | Retisert, Iluvien (Fluocinolone acetonide) |
| Particulate Systems | Targeted, sustained release; Variable (Days-Months) | ↑Bioavailability, ↓Toxicity, Cross barriers | Complex manufacturing, Stability issues | Liposomes (Verteporfin), Nanoparticles |
Emerging Ophthalmic NDDS - Eye‑Tech Horizons
- Gene Therapy: Viral (AAV) & non-viral vectors for sustained intraocular drug production (e.g., anti-VEGF). Targets retinal dystrophies, AMD.
- Cell-Based Delivery: Encapsulated Cell Technology (ECT) for continuous, long-term protein delivery.
- Stimuli-Responsive Systems:
- Smart Hydrogels: Drug release triggered by pH, temperature, light.
- Nanocarriers: Nanoparticles, liposomes for targeted delivery, enhanced penetration.
- Iontophoresis: Non-invasive transcorneal/transscleral drug delivery via electric current.
- Microneedles: Minimally invasive arrays for precise suprachoroidal/intrascleral drug placement.
⭐ Microneedles enable minimally invasive suprachoroidal or intrascleral drug delivery, enhancing local efficacy and reducing systemic exposure.
High‑Yield Points - ⚡ Biggest Takeaways
- Novel drug delivery systems (NDDS) enhance ocular bioavailability, prolong drug action, and improve patient compliance.
- Examples: liposomes, nanoparticles, hydrogels, microneedles, and ocular inserts (e.g., Lacrisert).
- Drug-eluting contact lenses provide continuous topical medication release.
- Intravitreal implants (e.g., Retisert, Ozurdex) offer long-term therapy for posterior segment diseases.
- Biodegradable polymers (e.g., PLGA) and non-biodegradable systems ensure sustained drug release.
- Key challenges: overcoming ocular barriers (cornea, BRB) and rapid tear turnover.
- Benefits include reduced dosing frequency and minimized systemic side effects.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app
